Resverlogix Quote - RVX

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.065

Bid

0.06

Ask

0.065

Volume

1,000

0.065 Day's Range 0.065

0.04 52 Week Range 0.095

Market Cap

17.704M

Previous Close

0.065

Open

0.065

Last Trade

1000

0.065

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

109,596

Shares Outstanding

272,371,000

Dividend Yield

PE Ratio

-0.98

Earnings Per Share (EPS)

-0.06

Revenue

57k

Net Profit

-16.74M

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.resverlogix.com

Headquarters

Calgary, Alberta, Can

Founded

Resverlogix Corp is listed in the Biological Pds,ex Diagnstics sector of the Toronto Stock Exchange with ticker RVX. The last closing price for Resverlogix was $0.07. Over the last year, Resverlogix shares have traded in a share price range of $ 0.04 to $ 0.095.

Resverlogix currently has 272,371,000 shares outstanding. The market capitalization of Resverlogix is $17.70 million. Resverlogix has a price to earnings ratio (PE ratio) of -0.98.

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalone’s...

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to...

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Reduction in the Risk of Major Adverse...

Resverlogix Announces Appointment of New Chief Scientific Officer

CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the appointment of Dr. Ewelina Kulikowski, Ph.D. as Chief Scientific Officer. Dr...

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary...

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D...

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company") (TSX:RVX), in partnership with EVERSANA™, today announced that the U.S. Food and Drug...

Resverlogix Announces One-Year Extension of Debenture

CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) announced today that it has closed a one-year extension of Company’s US$6.0...

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “BET Protein Inhibition for Pulmonary...

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

CALGARY, Alberta, March 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), a global leader in the development of epigenetic therapeutics, today announced that Donald...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0.065	0.065	0.06	14940	0.065	CS
4	0.01	18.1818181818	0.055	0.07	0.05	55680	0.06326648	CS
12	0.005	8.33333333333	0.06	0.095	0.045	109596	0.07336061	CS
26	0.01	18.1818181818	0.055	0.095	0.04	67968	0.06863809	CS
52	-0.01	-13.3333333333	0.075	0.095	0.04	53426	0.06725171	CS
156	-0.545	-89.3442622951	0.61	0.82	0.04	67305	0.19767345	CS
260	-1.045	-94.1441441441	1.11	1.94	0.04	67671	0.52663917	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
FLNTFlint Corporation	$ 0.025 (25.00%)	43k
SFDNXT Energy Solutions Inc	$ 0.20 (14.29%)	46.5k
CFFConifex Timber Inc	$ 0.53 (13.98%)	12.5k
GAugusta Gold Corp	$ 1.10 (12.24%)	90.61k
FORAVerticalScope Holdings Inc	$ 8.08 (10.38%)	54.08k
XMF.AM Split Corp	$ 0.25 (-50.00%)	39k
BCTBriaCell Therapeutics Corp	$ 1.02 (-13.56%)	23.17k
BYLBaylin Technologies Inc	$ 0.51 (-10.53%)	38.26k
RAY.BStingray Group Inc	$ 6.12 (-10.00%)	1,000
YRBYorbeau Resources Inc	$ 0.045 (-10.00%)	891.47k
BMOBank of Montreal	$ 127.75 (-1.38%)	7.68M
TDToronto Dominion Bank	$ 77.39 (0.09%)	7.07M
ENBEnbridge Inc	$ 56.44 (0.34%)	5.75M
MFCManulife Financial Corporation	$ 41.66 (-0.55%)	4.9M
CNQCanadian Natural Resources Ltd	$ 47.50 (-0.84%)	3.77M